Journal article
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: patient level meta-analysis of 7,030 women in four randomised trials
- Abstract:
-
Background: For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in postmenopausal women but are ineffective in premenopausal women when used without ovarian suppression. We aimed to investigate whether premenopausal women treated with ovarian suppression benefit from aromatase inhibitors.
Methods: We...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 1.4MB, Terms of use)
-
- Publisher copy:
- 10.1016/S1470-2045(21)00758-0
Authors
Contributors
+ Bradbury, R
- Institution:
- University of Oxford
- Division:
- MSD
- Department:
- Nuffield Department of Population Health
- Role:
- Contributor
+ Braybrooke, J
- Role:
- Contributor
+ Gray, R
- Role:
- Contributor
+ Hills, R
- Role:
- Contributor
+ Liu, Z
- Role:
- Contributor
- Publisher:
- Elsevier
- Journal:
- The Lancet Oncology More from this journal
- Volume:
- 23
- Issue:
- 3
- Pages:
- 382-392
- Publication date:
- 2022-02-28
- Acceptance date:
- 2021-12-17
- DOI:
- EISSN:
-
1474-5488
- ISSN:
-
1213-9432, 1470-2045
- Language:
-
English
- Keywords:
- Pubs id:
-
1226833
- Local pid:
-
pubs:1226833
- Deposit date:
-
2021-12-23
- ARK identifier:
Terms of use
- Copyright holder:
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
- Copyright date:
- 2022
- Rights statement:
- © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licence.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record